London, January 18, 2017.- ADAPT SMART’s General Assembly, held at the European Medicines Agency (EMA), agrees to focus its final year on incorporating stakeholder feedback into the development of Medicines Adaptive Pathways to Patients (MAPPs) tools and methodologies. Myeloma Patients Europe (MPE) was attending this meeting. With growing international interest and visibility in the final…
A coalition of 60 patient advocates, healthcare professionals and scientists (including 3 Nobel Prize winners) from 20 European countries have come together to publish a blueprint for improving cancer outcomes and achieving better quality of life for cancer survivors throughout Europe.1 They are members of the European Cancer Concord (ECC®), an equal partnership between patients…
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2016. The talk will be given by Dr Laurent Garderet, Department of Hematology, Saint Antoine Hospital, Paris,…
Brussels/Salamanca, January 9, 2017. The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies. Other organisations such as…
At the ESMO 2016 Congress held in Copenhagen between 7th-11th October, Dr Katja Weissel, from the Haematology and Oncology Department of Medicine at University Hospital Tuebingen (Germany), presented the results of the CASTOR study, a phase III randomised controlled study of daratumumab, bortezomib and dexamethasone (DVd) compared with bortezomib and dexamethasone (Vd) in patients with…
MPE, in collaboration with other patient organisations, is conducting a project to analyse legal agreements of pharmaceutical companies with patient advocates. The project will make suggestions for simpler, more understandable agreements that would sufficiently reflect and protect the interests of both parties.
Ixazomib (Ninlaro®) has received a positive recommendation from the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) for its use in relapsed myeloma patients. The decision follows an initial negative CHMP recommendation that was appealed by the pharmaceutical company, Takeda.
Myeloma Patients Europe (MPE), in close collaboration with Myeloma UK, and along with almost 30 member and non-member associations across Europe, has submitted a letter to the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) to encourage them to reconsider the negative recommendation for ixazomib, and provide information to the appeal…
